(Top to bottom) Stephen Haitz and Shawn Cavanagh
Cambrex Corporation, the small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has changed its management team and Board of Directors to accelerate growth and further operational excellence, building upon its trusted reputation for the highest quality pharmaceutical development and manufacturing capabilities.
The following appointments and new positions are effective immediately.
The Company’s Board of Directors will now be comprised of Chairman Wayne Hewett, CEO Steven Klosk, President Shawn Cavanagh, Claes Glassell, who will be rejoining the Board, Permira Partners John Coyle and Henry Minello and Permira Principal Laura O’Donnell.
Steven Klosk, CEO of Cambrex, said: “I’m proud of the depth and experience of our talented team, which is reflected in the quality of individuals transitioning to these leadership roles. We are well-positioned for continued growth in the market given our best-in-class assets, broad product capabilities and customer reputation. I’m thrilled to be working with this group of individuals and look forward to the strong future ahead.”